Turn Therapeutics (TTRX) director reports 40,030-share stock option on Form 3

Rhea-AI Filing Summary

Turn Therapeutics Inc. director Martin William Dewhurst filed an initial ownership report showing a stock option to buy 40,030 shares of common stock at an exercise price of $4.59 per share. The option became exercisable for 10,000 shares on July 26, 2024 and for 858 shares on the last day of each month thereafter, reflecting a 2-for-1 stock split that took effect on September 30, 2025. The option expires on July 26, 2034 and is held directly.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Dewhurst Martin William

(Last) (First) (Middle)

C/O TURN THERAPEUTICS INC.

250 N. WESTLAKE BLVD.

(Street)

WESTLAKE VILLAGE CA 91362

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/07/2026

3. Issuer Name and Ticker or Trading Symbol
Turn Therapeutics Inc. [ TTRX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	07/26/2034	Common Stock	40,030(2)	$4.59(2)	D

Explanation of Responses:

1. The stock option became exercisable as to 10,000 of the shares of common stock on July 26, 2024, and 858 shares on the last day of each month thereafter, in each case, after giving effect to the stock split as described below.

2. The number of shares of common stock underlying the stock option and the applicable exercise price give effect to the 2-for-1 forward stock split, that took effect on September 30, 2025.

Remarks:

Exhibit 24 - Power of Attorney.

	/s/ Zuraiz Chaudhary, attorney-in-fact for Martin William Dewhurst	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider position does the Form 3 show for Turn Therapeutics Inc. (TTRX)?

The Form 3 shows director Martin William Dewhurst holding a stock option for 40,030 shares of Turn Therapeutics common stock. This option represents his reported initial derivative beneficial ownership position in the company as of the stated event date.

What are the key terms of Martin Dewhurst’s stock option in Turn Therapeutics (TTRX)?

Martin Dewhurst’s stock option covers 40,030 common shares with an exercise price of $4.59 per share and an expiration date of July 26, 2034. The option is held directly and reflects adjustments from a later stock split.

How does Martin Dewhurst’s Turn Therapeutics (TTRX) option vest over time?

The option became exercisable for 10,000 shares on July 26, 2024, then for 858 shares on the last day of each subsequent month. This schedule, including share counts, already incorporates the effects of the company’s 2-for-1 forward stock split.

How did Turn Therapeutics’ 2-for-1 stock split affect this Form 3 option grant?

The Form 3 states that both the 40,030 option shares and the $4.59 exercise price give effect to a 2-for-1 forward stock split that took effect on September 30, 2025, meaning the figures shown are already split-adjusted.

Is Martin Dewhurst’s Turn Therapeutics (TTRX) stock option held directly or indirectly?

The filing identifies the stock option as held directly by Martin Dewhurst. No indirect ownership vehicle, such as a trust or LLC, is listed in the ownership form or the accompanying explanatory footnotes.

What is the event date for Martin Dewhurst’s Form 3 with Turn Therapeutics (TTRX)?

The event date associated with this Form 3 is January 7, 2026. As of that date, the filing records Martin Dewhurst’s beneficial ownership of the stock option covering 40,030 shares of Turn Therapeutics common stock under the disclosed terms.